CRSP Healthcare

CRISPR Therapeutics AG

$49.99+0.00%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: Switzerland
Market cap: 4.8B USD
Enterprise value: 3.0B USD

Overall health

Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity
Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 1.76 vs a peer median of 0.63)bigger price swings (beta 1.76 vs peers 0.63)

Ranks #1,018 of 1,157 healthcare companies (bottom 13%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 23% from December 2022 to July 2026.
CRISPR Therapeutics had 23% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.CRISPR Therapeutics had 23% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Stock-based pay is a large cost. Stock pay was 2065% of revenue in 2025.
CRISPR Therapeutics paid employees $72M in stock in 2025, 2065% of its $4M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, CRISPR Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
CRISPR Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

27/ 100

Oct 5 27 → Nov 4 27

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-9.3%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-16.9%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-7.7%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield36.1%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

5/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 226.4%

Why

Weaker than most peers on:

▼ 3-yr revenue
▼ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth-57.1%

SEC filings · 3 years to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -3.70Sector median: 0.0584 · MAD: 0.0840

Revenue growth-64.8%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -4.87Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

5/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-3990.0%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -71.87Sector median: 0.0706 · MAD: 0.1217

Return on assets-17.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -3.48Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-20.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -2.53Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-25.8%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.76

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -3.36Sector median: 0.6250 · MAD: 0.3380

Current ratio17.85×

SEC filings · latest balance sheetReported value33% base weight · Z-score 11.02Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.34×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.56Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about CRISPR Therapeutics

Is CRISPR Therapeutics getting weaker?: Its latest SEC filing (Aug 3, 2026) showed no major changes. Its overall score is unchanged at 27/100 since Oct 28, 2026.
How is CRISPR Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -9.3% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -9.3% vs peers 1.5% (weaker than 100% of peers).
Is CRISPR Therapeutics growing?: More slowly than most of its peers. Growth scores 5/100 against 1,393 healthcare peers. 3-year revenue growth -57.1% vs a peer median of 5.8% (weaker than 100% of peers).3-year revenue growth -57.1% vs peers 5.8% (weaker than 100% of peers).
How profitable is CRISPR Therapeutics?: Less profitable than most of its peers. Profitability scores 5/100 against 1,393 healthcare peers. Operating margin -3990.0% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -3990.0% vs peers 7.1% (weaker than 100% of peers).
How risky is CRISPR Therapeutics?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 17.85× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 17.85× vs peers 2.59× (stronger than 95% of peers). Beta 1.76 vs a peer median of 0.63 (weaker than 91% of peers).Beta 1.76 vs peers 0.63 (weaker than 91% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 3, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

Worth watching: CRISPR Therapeutics is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	4.1M USD	13.4M USD	+226.4%
Net income (12 months)	−568.5M USD	−451.1M USD	−20.6%
Operating margin	-15754.2%	-3990.0%	+11764.2 pts
Free cash flow (12 months)	−401.2M USD	−371.3M USD	−7.4%
Debt	585.5M USD	586.2M USD	+0.1%
Cash	423.3M USD	291.3M USD	−31.2%
Shares outstanding	96.4M	96.7M	+0.3%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Operating margin	40.8%	-56190.4%	-60.0%	-1250.4%	-18933.6%	▼ >999 pts
Net margin	41.3%	-54271.7%	-41.4%	-981.5%	-16569.8%	▼ >999 pts
Return on assets (ROA)	13.7%	-29.0%	-6.9%	-16.3%	-25.7%	▼ 9.3 pts
Return on equity (ROE)	15.7%	-34.7%	-8.2%	-19.0%	-30.3%	▼ 11 pts
Free cash flow margin	50.0%	-44484.9%	-72.7%	-387.7%	-9855.5%	▼ >999 pts
Current ratio	20.17×	15.30×	17.54×	22.07×	13.32×	▼ 40%

CRSP price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 1.76 vs a peer median of 0.63)bigger price swings (beta 1.76 vs peers 0.63)

Ranks #1,018 of 1,157 healthcare companies (bottom 13%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 23% from December 2022 to July 2026.

CRISPR Therapeutics had 23% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.CRISPR Therapeutics had 23% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Stock-based pay is a large cost. Stock pay was 2065% of revenue in 2025.

CRISPR Therapeutics paid employees $72M in stock in 2025, 2065% of its $4M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, CRISPR Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

CRISPR Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about CRISPR Therapeutics

Is CRISPR Therapeutics getting weaker?

Its latest SEC filing (Aug 3, 2026) showed no major changes. Its overall score is unchanged at 27/100 since Oct 28, 2026.

How is CRISPR Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -9.3% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -9.3% vs peers 1.5% (weaker than 100% of peers).

Is CRISPR Therapeutics growing?

More slowly than most of its peers. Growth scores 5/100 against 1,393 healthcare peers. 3-year revenue growth -57.1% vs a peer median of 5.8% (weaker than 100% of peers).3-year revenue growth -57.1% vs peers 5.8% (weaker than 100% of peers).

How profitable is CRISPR Therapeutics?

Less profitable than most of its peers. Profitability scores 5/100 against 1,393 healthcare peers. Operating margin -3990.0% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -3990.0% vs peers 7.1% (weaker than 100% of peers).

How risky is CRISPR Therapeutics?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 17.85× vs a peer median of 2.59× (stronger than 95% of peers).Current ratio 17.85× vs peers 2.59× (stronger than 95% of peers). Beta 1.76 vs a peer median of 0.63 (weaker than 91% of peers).Beta 1.76 vs peers 0.63 (weaker than 91% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

4.1M USD

13.4M USD

+226.4%

Net income (12 months)

−568.5M USD

−451.1M USD

−20.6%

Operating margin

-15754.2%

-3990.0%

+11764.2 pts

Free cash flow (12 months)

−401.2M USD

−371.3M USD

−7.4%

Debt

585.5M USD

586.2M USD

+0.1%

Cash

423.3M USD

291.3M USD

−31.2%

Shares outstanding

96.4M

96.7M

+0.3%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Operating margin

40.8%

-56190.4%

-60.0%

-1250.4%

-18933.6%

▼ >999 pts

Net margin

41.3%

-54271.7%

-41.4%

-981.5%

-16569.8%

▼ >999 pts

Return on assets (ROA)

13.7%

-29.0%

-6.9%

-16.3%

-25.7%

▼ 9.3 pts

Return on equity (ROE)

15.7%

-34.7%

-8.2%

-19.0%

-30.3%

▼ 11 pts

Free cash flow margin

50.0%

-44484.9%

-72.7%

-387.7%

-9855.5%

▼ >999 pts

Current ratio

20.17×

15.30×

17.54×

22.07×

13.32×

▼ 40%